Login / Signup

Gut Serpinome: Emerging Evidence in IBD.

Héla MkaouarVincent MariauleSoufien RhimiJuan HernandezAicha KriaaAmin JablaouiNizar AkermiEmmanuelle MaguinAdam LesnerBrice KorkmazMoez Rhimi
Published in: International journal of molecular sciences (2021)
Inflammatory bowel diseases (IBD) are incurable disorders whose prevalence and global socioeconomic impact are increasing. While the role of host genetics and immunity is well documented, that of gut microbiota dysbiosis is increasingly being studied. However, the molecular basis of the dialogue between the gut microbiota and the host remains poorly understood. Increased activity of serine proteases is demonstrated in IBD patients and may contribute to the onset and the maintenance of the disease. The intestinal proteolytic balance is the result of an equilibrium between the proteases and their corresponding inhibitors. Interestingly, the serine protease inhibitors (serpins) encoded by the host are well reported; in contrast, those from the gut microbiota remain poorly studied. In this review, we provide a concise analysis of the roles of serine protease in IBD physiopathology and we focus on the serpins from the gut microbiota (gut serpinome) and their relevance as a promising therapeutic approach.
Keyphrases
  • end stage renal disease
  • chronic kidney disease
  • ulcerative colitis
  • protein kinase
  • ejection fraction
  • newly diagnosed
  • magnetic resonance
  • risk factors
  • prognostic factors
  • molecular dynamics